INTRODUCTION
============

The Runt-related transcription factor (RUNX) family consists of three members, which share the highly conserved 'Runt' DNA-binding domain that associates with their co-factor, core binding factor β (CBFβ). All three RUNX proteins and CBFβ exert tumor-related functions in context-dependent manners. RUNX3 is the least studied member of the family, as it has been reported to act as both a tumor-suppressor and oncogene in human cancers. Initially, its broad tumor-suppressive function attracted attention, originating from observations of gastric phenotypes in *Runx3-*knockout mice and the causal relationship between *RUNX3*-silencing and human gastric cancer ([@ref39]). RUNX3 inactivation occurs due to genetic/epigenetic alteration or protein mislocalization in a diverse range of human cancers, including gastric, colorectal, lung, pancreas, breast, liver, and prostate cancers as well as leukemia and neuroblastoma. On the other hand, RUNX3 upregulation has been observed in various cases of human malignant tumors, suggesting that it plays oncogenic roles ([@ref13]; [@ref31]). In these cases, RUNX3 stimulates cell proliferation, inhibits apoptosis, confers drug resistance, and promotes tumorigenicity in human cancers ([Table 1](#T1){ref-type="table"}), implying that oncogenic RUNX3 is related to tumor malignancy, invasiveness and metastasis.

###### 

Oncogenic functions of RUNX3 reported so far

  Cancer type                   Oncogenic RUNX3 functions        References
  ----------------------------- -------------------------------- -----------------------------------------
  AML                           Drug resistance acquisition      ([@ref18])
  T-ALL                         Apoptosis inhibition             ([@ref16])
  Basal cell carcinoma          Cell growth stimulation          ([@ref34])
  Head and neck cancer          Cell growth stimulation          ([@ref65])
  Ovarian cancer                Tumorigenicity enhancement       ([@ref3]; [@ref12]; [@ref33]; [@ref48])
  Drug resistance acquisition                                    
  Cell growth stimulation                                        
  Pancreatic cancer             Metastasis promotion *in vivo*   ([@ref68])
  Ewing's sarcoma               Tumorigenicity enhancement       ([@ref6])

The past two decades of RUNX3 research have further clarified its original tumor-suppressive functions, but have also elaborated its opposing roles as an oncogene, provoking an essential question: how is the dual nature of RUNX3 determined by cellular context? Given the potential medical value of targeting the RUNX transcription factors, the demand for an answer to this question continues to grow ([@ref9]; [@ref17]; [@ref44]). As we will show below, RUNX3 acts as a tumor-suppressor when interacting with p53, but as a tumor promoter when associating with MYC. These observations led us to focus on p53 and MYC, two central figures in tumor development, as contextual determinants of the duality of RUNX3.

RUNX3 AND p53
=============

RUNX3 acts as a positive regulator for p53, the quintessential gatekeeper and guardian of the genome, under two circumstances: upon DNA damage or upon oncogene activation ([@ref2]; [@ref36]). In the former case, RUNX3 is induced by DNA damage, forms a complex with p53, and facilitates its modifications (i.e., phosphorylation at Ser-15), thereby stabilizing p53 activity and promoting apoptosis ([@ref51]; [@ref70]). On the other hand, RUNX3 is also activated by oncogenic KRAS and indirectly stabilizes p53 by transcriptionally upregulating *p14ARF* (*p19Arf* in mice; hereafter *ARF*) in collaboration with pRB and BRD2, serving as a counterbalance to MDM2-mediated p53 degradation ([@ref37]; [@ref35]). Importantly, whether it is invoked by DNA damage or oncogenic stress, the tumor-suppressive functions of RUNX3 seem to be largely dependent on an intact p53 pathway.

Another oncogenic stress that invokes the ARF--p53 pathway is MYC ([@ref22]; [@ref46]; [@ref53]; [@ref58]; [@ref75]), a master regulator of cell proliferation broadly involved in the pathogenesis of human cancer. Indeed, MYC transcriptionally activates RUNX3 in NKTL (natural killer/T-cell lymphoma) cells ([@ref59]), suggesting that MYC, as well as KRAS, is one of the oncogenes that trigger the RUNX3--ARF--p53 pathway. p53 protects against MYC either directly, by transcriptional repression ([@ref27]; [@ref54]), or indirectly, via miR-145 induction ([@ref57]). Moreover, *MYC*-driven lymphomagenesis *in vivo* is dramatically increased by *p53* disruption ([@ref8]; [@ref22]; [@ref58]) and inhibited by *p53* restoration ([@ref43]).

Once activated by RUNX3, p53 seems to repress RUNX3 function. Aberrant upregulation of Runx3 coincides with the apparent loss of heterozygosity (LOH) of *p53* in a pancreatic cancer model, the *Kras^LSL-G12D/+^;p53^LSL-R172H/+^;p48Cre* (*KPC*) mice ([@ref68]). *Runx3* and *Runx1* mRNA levels are upregulated upon *p53*-knockout in some primary mesenchymal cells ([@ref62]). Also, Runx2 expression increases upon inactivation of p53 in both primary osteoblasts and bone marrow mesenchymal stromal cells ([@ref25]; [@ref38]; [@ref63]). In terms of mechanism, miR-34, one of the best studied miRNAs induced by p53 ([@ref24]; [@ref49]), downregulates expression of *Runx3* ([@ref56]) and *Runx2* ([@ref25]; van der [@ref66]). RUNX3 contributes to the functional activity of p53 either directly, by binding it, or indirectly, via *ARF* induction, but excessive p53 activity would doubtless lead to undesired side effects.

If the tumor-suppressive functions of RUNX3 are governed by p53 in this manner, p53 inactivation might be the very event that triggers Runx3 dysregulation and its conversion to an oncogene. In fact, upregulation of Runx3 in *KPC* mice in which *p53* has undergone LOH facilitates pancreatic cancer metastasis ([@ref68]). Also, upon p53 loss, Runx1 accelerates tumorigenicity in mouse embryonic fibroblast cells ([@ref69]), and heterozygous deletion of *Runx1* in *p53*-null mice decreases the incidence of thymic lymphoma, thus lengthening their lifespans ([@ref62]). In addition, *Runx2*-induced lymphomagenesis shortens the lifespans of *p53*-null mice, but no such effect is observed in *p53*-heterozygous mice ([@ref7]).

p53 hotspot mutations might also contribute to the oncogenic conversion of Runx3. p53 hotspot mutants, exemplified by p53^R175H^ (p53^R172H^ in mice), possess oncogenic (gain-of-function) properties in addition to defects in tumor suppression ([@ref20]). As mentioned above, wild-type p53 promotes its own tumor-suppressive activities by directly interacting with RUNX3, whereas p53 hotspot mutants do not follow suit. On the contrary, it is suggested that p53^R175H^ is also capable of directly interacting with RUNX3, and that the p53^R175H^--RUNX3 complex is aberrantly stable and exerts its oncogenic activities by altering the transcriptional targets of each of its components ([@ref67]; [@ref68]). In fact, p53^R175H^ is involved in the switching of transforming growth factor β (TGF-β) signaling from a tumor-suppressor to a tumor-promoter ([@ref1]); TGF-β requires tumor-suppressive RUNX3 to exert some of its anti-tumor effects ([@ref10]; [@ref15]; [@ref28]; [@ref71]). In line with this series of evidence, *p53* deficiency most likely causes oncogenicity of RUNX3 in human carcinogenesis ([Fig. 1](#F1){ref-type="fig"}).

![p53 status as a contextual determinant of the duality of RUNX3.\
Following DNA damage or oncogenic stress, RUNX3 positively regulates p53 and is in turn suppressed by it; p53 then prevents tumorigenesis by decreasing the activity of crucial oncogenes such as MYC (left). Upon inactivation of p53, dysregulated RUNX3 starts to aberrantly upregulate MYC (right). Thus, p53 status is a contextual determinant for whether RUNX3 behaves as a tumor-suppressor or oncogene.](molce-43-176-f1){#F1}

RUNX3 AND MYC
=============

As listed in [Table 1](#T1){ref-type="table"}, several lines of evidence have revealed the oncogenic behavior of RUNX3 in multiple types of cancer. Unfortunately, most of these studies have not been able to identify the precise molecular mechanisms underlying the oncogenic phenotypes observed, although these phenotypes can be attributed to aberrant RUNX3 upregulation. We propose that the association of RUNX3 with MYC under p53 deficiency can resolve this enigma.

By retrovirus insertional mutagenesis, all *Runx* family genes have been identified as frequent targets in *MYC*-induced lymphoma ([@ref23]; [@ref47]), and these findings were further corroborated by RUNX proteins' positive correlation with MYC in certain types of leukemia ([@ref16]; [@ref32]; [@ref59]). In T-cell acute lymphoblastic lymphoma (T-ALL), RUNX3 and RUNX1 bind the +1.43 Mb *MYC* enhancer *N-Me* and upregulate MYC in KOPT-K1 cells ([@ref16]). This long-range distal super enhancer of *MYC*, consisting of multiple RBPJ sites, directly converts aberrant NOTCH1 signaling to MYC dysregulation. *Myc* regulation via *N-Me* is essential for T-cell development and tumorigenesis of *NOTCH1*-induced T-ALL in mice. The relevance of *N-Me* to human T-ALL pathogenesis is supported by the identification of a chromosomal focal amplification at this enhancer in \~5% of human T-ALL cases ([@ref5]; [@ref26]). Thus, RUNX3 binding to *N-Me* might at least partly explain its oncogenic contribution to T-ALL development. It should also be noted, however, that in acute myeloid leukemia (AML), RUNX1 and its co-factor CBFβ inhibit MYC expression by binding *BDME*, another *MYC* enhancer 0.4 Mb downstream of *N-Me*, supporting the ideas that RUNX1 plays tumor-suppressive/oncogenic roles on diverse enhancers across leukemia subtypes ([@ref9]; [@ref55]; [@ref61]). Importantly, activation of this RUNX3--MYC axis may depend on p53-deficiency. The major cancer type to which *p53*-deficient mice succumb is thymic lymphoma ([@ref20]). Moreover, in lymphomas, the most frequently observed somatic alterations are in *CDKN2A* ([@ref42]), which encodes *ARF* and *p16^INK4A^*, conferring the same benefits as p53 deficiency ([@ref60]), and alterations of *TP53* itself is also an independent prognostic indicator ([@ref50]; [@ref73]).

In bone-related cells, RUNX3 is highly upregulated across several Ewing's sarcoma cell lines and facilitates their cell growth ([@ref6]). Notably in this regard, RUNX2 binds and epigenetically activates the *MYC* regulatory element to induce upregulation of MYC. Indeed, individual knockdown of *RUNX2* or *MYC* abolishes tumorigenicity of SaOS2, a human osteosarcoma cell line ([@ref63]). The same mechanism might be applicable to RUNX3, considering that functions of both Runx2 and Runx3 are required during bone development ([@ref72]). Moreover, experiments in osteoblast-specific Runx3-deficient mice clearly showed that Runx3 is non-redundantly required for the proliferation of pre-committed cells to generate adequate numbers of active osteoblasts, whereas Runx2 is mandatory for osteoblastic lineage commitment ([@ref4]). Importantly, Ewing's sarcoma and osteosarcoma, the most common primary malignant bone tumors, both tend to undergo recurrent *TP53* mutations ([@ref11]; [@ref64]).

Taken together, these observations suggest the following model: in a cell governed by the tumor-suppressor p53, RUNX3 is invoked by either DNA damage or oncogenic stress, and positively regulates p53, which protects against MYC. Upon p53 inactivation, however, RUNX3 is unable to properly associate with p53, and therefore begins to act as an oncogene by aberrantly activating MYC ([Fig. 1](#F1){ref-type="fig"}).

Previously, we reported that RUNX3 prevents tumorigenesis of the gastrointestinal tract, possibly by repressing MYC. This may appear to contradict our proposal that MYC is activated by RUNX3. In mechanistic terms, RUNX3 attenuates the DNA-binding activity of the TCF4/β-catenin complex that induces MYC, the principal oncogene for gastrointestinal cancer ([@ref30]; [@ref29]). It should be noted, however, that this tumor-suppressive role of RUNX3 was demonstrated in precancerous states using systemic *Runx3-*decifient mouse lines, without reference to p53 status *in vivo*. It remains to be determined whether RUNX3 continues to function as a tumor-suppressor by repressing MYC even after p53 is inactivated.

CONCLUSIONS AND PERSPECTIVES
============================

We proposed p53 status as a contextual determinant of the dual nature of RUNX3. In this model, p53 inactivation is the crucial event responsible for causing RUNX3 to contribute to cancer development. If that is the case, p53 deficiency and MYC dysregulation, two major phenomena related to most cancer initiation and progression in humans, may be connected by RUNX3, providing a rationale for targeting RUNX3 in malignancies ([Fig. 2](#F2){ref-type="fig"}).

![RUNX3 connects p53 deficiency and MYC dysregulation.\
Are p53 deficiency and MYC dysregulation, two principal phenomena associated with tumor development, connected by RUNX3?](molce-43-176-f2){#F2}

Indeed, Runx3 evidently does help to repress tumorigenesis in mouse models of gastrointestinal and lung cancers, but the *p53* status of these tumors has not been considered. Validation of our hypothesis will require more sophisticated mouse models in which *Runx3* or *p53* are disrupted in a tissue-specific or temporally specific manner. Also, the genomic elements responsible for upregulation of Myc by Runx3, such as *N-Me*, should be studied further. In particular, it should be determined whether depletion of a specific element, such as a specific RUNX binding site, would suppress tumorigenesis in animal cancer models.

In fact, several other transcription factors play dual roles in cancer development: NF-κB in TNF-α signaling ([@ref52]); SMADs in TGF-β signaling ([@ref19]); AP-1 in MAPK signaling ([@ref21]); YAP/TAZ in Hippo signaling ([@ref45]); and RBPJ in Notch signaling ([@ref41]). Many of these signal-driven transcription factors (SDTFs) ([@ref74]) interact with RUNX3 ([@ref14]). RUNX family members are thought to be lineage-determining transcription factors (LDTFs) that specify cell identity and determine the genome-wide binding pattern of SDTFs over the course of normal development ([@ref40]; [@ref74]). Thus, a contextual determinant of the dual nature of RUNX3 might be shared by other transcription factors.
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